Future of pharmaceutical policy rests on secure supply of essential medicines

The recently published EU pharmaceutical revision aims to improve medicines affordability, accessibility, and availability in Europe. The secure supply of essential medicines is the foundation to achieve these goals.

Open

Patients should benefit from greater access under new patent package proposals

Reaction to EU Pharmaceutical legislation: Timely and equitable access for patients and security of supply essential for reform

Harmonised bioequivalence guideline paves the way for global generic medicine development and access to medicines

Market reforms needed to secure essential antibiotics against AMR, report says

Recent shortages of essential antibiotics in Europe have renewed the urgency to reform the pricing and industrial infrastructure for these essential medicines. The off-patent sector manufactures and supplies most antibiotics in Europe needed to control bacterial infections. Pricing policies for these antibiotics must urgently be reviewed so that they remain viable to produce and supply.

Open

OPEN LETTER Time for a new medicine security contract for Europe

The purpose of Medicines for Europe members is to improve access to medicines and provide a better availability and supply security for European patients. However, the current situation is challenging our ability to fulfil this objective.

Open

EU can do more for equitable access to medicines

The Hungarian Permanent Representation to the European Union hosted the event “Sustainable ways to finance innovation” organised in collaboration with the Slovak Presidency of the Visegrad 4 Group, the Permanent Representation of the Netherlands and Medicines for Europe

 

Open

IGBA taking action to tackle shortages of antibiotic medicines

The global generic medicines industry supplies most of the world’s antibiotic medicine and is aware of the surge in demand of these products that is leading to shortages. The surge is driven by an unusually high rate of respiratory conditions and infections that are occurring as we exit the most acute phase of the Covid-19 pandemic and, in many countries, an unusually high rate of respiratory conditions and infections among children.

 

Open

Commission study highlights need for procurement reform to ensure patient access to medicines

To improve access to medicines, we need European-wide legal guidance on medicines procurement covering security of supply, MEAT criteria and biosimilar competition.

Open

Billions more euros to re-invest in better healthcare thanks to biosimilar medicines

Biosimilar medicines deliver access for patients suffering from serious and debilitating conditions such as cancer, auto immune diseases, and diabetes. The benefits of using biosimilar medicines center on increasing the number of patients treated, leading to better health, and further advantages to health systems and healthcare professionals.

 

Open